161 related articles for article (PubMed ID: 38116673)
1. Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study.
Zheng C; Liu Y; Wang X; Bi Z; Qiu P; Qiao G; Bi X; Shi Z; Zhang Z; Chen P; Sun X; Wang C; Zhu S; Meng X; Song Y; Qi Y; Li L; Luo N; Wang Y
Int J Surg; 2024 Mar; 110(3):1527-1536. PubMed ID: 38116673
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial.
Wang C; Liu Z; Chen X; Qiao J; Lu Z; Li L; Sun X; Zhang C; Yue X; Xia Q; Zhang H; Yan M
Nat Commun; 2023 Oct; 14(1):6654. PubMed ID: 37863916
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
7. Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.
Chen G; Gu X; Xue J; Zhang X; Yu X; Zhang Y; Li A; Zhao Y; He G; Tang M; Xing F; Yin J; Bian X; Han Y; Cao S; Liu C; Jiang X; Zhang K; Xia Y; Li H; Niu N; Liu C;
Elife; 2023 Dec; 12():. PubMed ID: 38131294
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
9. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C; Mittendorf EA; Garber HR; Sun R; Damodaran S; Murthy RK; Ramirez D; Karuturi M; Layman RM; Ibrahim N; Rauch GM; Adrada BE; Candelaria RP; White JB; Ravenberg E; Clayborn A; Ding QQ; Symmans WF; Prabhakaran S; Thompson AM; Valero V; Tripathy D; Huo L; Moulder SL; Litton JK
Breast Cancer Res Treat; 2023 Jun; 199(3):457-469. PubMed ID: 37061619
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
12. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
13. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Liang Y; Liu J; Ge J; Shi Q; Zhang G; Wan A; Luo T; Tian H; Fan L; Wang S; Chen L; Tang P; Zhu K; Jiang J; Bian X; Zhang Y; Qi X
EClinicalMedicine; 2024 May; 71():102585. PubMed ID: 38638401
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract][Full Text] [Related]
20. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
